TD Cowen analyst Mathew Blackman initiated coverage of SI-Bone (SIBN) with a Buy rating and $21 price target An exclusive focus on sacropelvic anatomy and a capital-light business model make SI-Bone “a unique musculoskeletal asset,” the analyst tells investors. With multiple growth-sustaining catalysts ahead and progress towards profitability, the firm views the company as positioned to exceed Street estimates, the analyst added.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SIBN:
- SI-Bone: Capital-Efficient Sacropelvic Leader Poised for Durable Mid-Teens Growth and Margin Expansion
- SI-BONE Reports Strong Preliminary Q4 and 2025 Revenue Growth
- SI-Bone reports preliminary Q4 revenue $56.2M-$56.3M, consensus $54.49M
- SI-Bone price target raised to $23 from $21 at Truist
- SI-Bone price target raised to $27 from $26 at Canaccord